公开(公告)号：US11414411B2

公开(公告)日：2022-08-16

申请号：US16635596

申请日：2018-08-01

Applicant: Novartis AG

Inventor： Like Chen ,  Chi Ming Cheung ,  Zhongbo Fei ,  Qun Jiang ,  Lei Li ,  Bin Li ,  Thomas Ruch ,  Hao Wang ,  Quanbing Wu

IPC: C07D417/14

Abstract: The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), or a salt thereof, or a solvate including hydrate thereof, and/or intermediates thereof, and the use of intermediates for preparing Compound X. In particular, the process relates to the preparation of Compound X using dynamic kinetic resolution (DKR) and asymmetric catalytic reduction, thereby providing an improved route to 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (Compound X) and compositions containing said compound, including the arginine salt, sodium salt and hydrated solid forms of Compound X.

公开(公告)号：US12138262B2

公开(公告)日：2024-11-12

申请号：US17280637

申请日：2019-09-18

Applicant: Novartis AG

Inventor： Zhongbo Fei ,  Gang Lu ,  Yinbo Wan ,  Jianhua Wang ,  Quanbing Wu ,  Hao Zhang

IPC: A61K31/497 ,  A61K45/06 ,  C07D491/107 ,  A61K31/438 ,  A61K31/496 ,  A61P35/00 ,  C07D211/22 ,  C07D211/62 ,  C07D213/127 ,  C07D213/61 ,  C07D401/12

Abstract: The invention relates to a method for the manufacture of a compound of Formula I as mentioned above, or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme: wherein A, LG, n and m are as defined in the Summary of the Invention.